U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

2014
503
Substance Class Protein
Created
by admin
on Mon Mar 31 18:40:52 GMT 2025
Edited
by admin
on Mon Mar 31 18:40:52 GMT 2025
Protein Type MONOCLONAL ANTIBODY
Protein Sub Type IGG1
Sequence Origin HUMANIZED MOUSE
Sequence Type COMPLETE
Record UNII
9RV78Q2002
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
VEDOLIZUMAB
DASH   INN   MART.   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
ENTYVIO
Preferred Name English
LDP02
Code English
MLN0002
Code English
Vedolizumab [WHO-DD]
Common Name English
MLN-02
Code English
VEDOLIZUMAB [PURPLE BOOK CDER]
Common Name English
VEDOLIZUMAB [MI]
Common Name English
LDP-02
Code English
IMMUNOGLOBULIN G1, ANTI-(HUMAN INTEGRIN LPAM-1 (LYMPHOCYTE PEYER'S PATCH ADHESION MOLECULE 1)) (HUMAN-MUS MUSCULUS HEAVY CHAIN), DISULFIDE WITH HUMAN-MUS MUSCULUS .KAPPA.-CHAIN, DIMER
Common Name English
VEDOLIZUMAB [USAN]
Common Name English
MLN02
Code English
MLN-0002
Code English
VEDOLIZUMAB [MART.]
Common Name English
VEDOLIZUMAB [VANDF]
Common Name English
vedolizumab [INN]
Common Name English
VEDOLIZUMAB [JAN]
Common Name English
Classification Tree Code System Code
FDA ORPHAN DRUG 558216
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
EMA ASSESSMENT REPORTS ENTYVIO (AUTHORIZED: CROHN DISEASE)
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
EMA ASSESSMENT REPORTS ENTYVIO (AUTHORIZED: COLITIS, ULCERATIVE)
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
NCI_THESAURUS C20401
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
FDA ORPHAN DRUG 804920
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
FDA ORPHAN DRUG 523516
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
NDF-RT N0000175775
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
WHO-ATC L04AA33
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
Code System Code Type Description
ChEMBL
CHEMBL1743087
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
DRUG BANK
DB09033
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
FDA UNII
9RV78Q2002
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
WIKIPEDIA
VEDOLIZUMAB
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
LACTMED
Vedolizumab
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
SMS_ID
100000093402
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
DAILYMED
9RV78Q2002
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
DRUG CENTRAL
4982
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
RXCUI
1538097
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY RxNorm
USAN
UU-48
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
CAS
943609-66-3
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
MERCK INDEX
m11728
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
EVMPD
SUB30452
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
INN
9093
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
IUPHAR
7437
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
NCI_THESAURUS
C95798
Created by admin on Mon Mar 31 18:40:52 GMT 2025 , Edited by admin on Mon Mar 31 18:40:52 GMT 2025
PRIMARY
From To
1_22 1_96
1_148 1_204
1_265 1_325
1_371 1_429
2_22 2_96
2_148 2_204
2_265 2_325
2_371 2_429
3_23 3_93
3_139 3_199
4_23 4_93
4_139 4_199
1_224 3_219
2_224 4_219
1_230 2_230
1_233 2_233
Glycosylation Type MAMMALIAN
Glycosylation Link Type Site
N 1_301
N 2_301
Related Record Type Details
INTEGRIN ALPHA-4 BETA-7
TARGET -> INHIBITOR
Inhibits binding to MADCAM1, preventing T cells from homing to the gut
Related Record Type Details
VEDOLIZUMAB
ACTIVE MOIETY
Ulcerative colitis and Crohn’s disease
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:ESTIMATED CHEMICAL
Volume of Distribution PHARMACOKINETIC
Molecular Formula CHEMICAL
NIH
NCATS
PRIVACY NOTICE
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966